首页> 美国卫生研究院文献>AAPS PharmSciTech >Comparative Study of Propranolol hydrochloride Release from Matrix Tablets with Kollidon®SR or Hydroxy Propyl Methyl Cellulose
【2h】

Comparative Study of Propranolol hydrochloride Release from Matrix Tablets with Kollidon®SR or Hydroxy Propyl Methyl Cellulose

机译:与Kollidon®SR或羟丙基甲基纤维素从基质片剂中释放盐酸普萘洛尔的比较研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The release of propranolol hydrochloride from matrix tablets with hydroxy propyl methyl cellulose (HPMC K15M) or Kollidon®SR at different concentrations was investigated with a view to developing twice daily sustained release dosage form. A hydrophilic matrix-based tablet using different concentrations of HPMC K15M or Kollidon®SR was developed using direct compression technique to contain 80 mg of propranolol hydrochloride. The resulting matrix tablets prepared with HPMC K15M or Kollidon®SR fulfilled all the official requirements of tablet dosage forms. Formulations were evaluated for the release of propranolol hydrochloride over a period of 12 h in pH 6.8 phosphate buffer using USP type II dissolution apparatus. Propranolol hydrochloride and pure Kollidon®SR or HPMC K15M compatibility interactions was investigated by using Fourier-transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC). FTIR spectroscopic and DSC studies revealed that there was no well defined chemical interaction between propranolol hydrochloride with Kollidon®SR or HPMC K15M. Tablets were exposed to 40 °C/75% of RH in open disc for stability. The in vitro drug release study revealed that HPMC K15 at a concentration of 40% of the dosage form weight was able to control the release of propranolol hydrochloride for 12 h, exhibit non-Fickian diffusion with first-order release kinetics where as at 40% Kollidon®SR same dosage forms show zero-order release kinetics. In conclusion, the in vitro release profile and the mathematical models indicate that release of propranolol hydrochloride can be effectively controlled from a single tablet using HPMC K15M or Kollidon®SR matrix system.
机译:研究了盐酸普萘洛尔从具有不同浓度的羟丙基甲基纤维素(HPMC K15M)或SR的基质片剂中的释放,以开发每日两次的持续释放剂型。使用直接压缩技术开发了使用不同浓度的HPMC K15M或Kollidon®SR的亲水性基质片剂,其中含有80 mg盐酸普萘洛尔。用HPMC K15M或Kollidon®SR制备的所得基质片剂满足片剂剂型的所有官方要求。使用USP II型溶出度仪评估制剂在pH 6.8磷酸盐缓冲液中12小时内盐酸普萘洛尔的释放情况。使用傅立叶变换红外(FTIR)光谱和差示扫描量热法(DSC)研究了盐酸普萘洛尔与纯Kollidon®SR或HPMC K15M的相容性相互作用。 FTIR光谱和DSC研究表明,盐酸普萘洛尔与SR或HPMC K15M之间没有明确定义的化学相互作用。将片剂暴露于开放盘中的40°C / 75%RH中以保持稳定性。体外药物释放研究表明,HPMC K15的剂量占剂型重量的40%能够控制盐酸普萘洛尔的释放达12小时,表现出非菲克扩散性,具有一级释放动力学,其中40%为Kollidon®SR相同剂型显示零级释放动力学。总之,体外释放曲线和数学模型表明,使用HPMC K15M或Kollidon®SR基质系统可以从单个片剂中有效控制盐酸普萘洛尔的释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号